Literature DB >> 8904419

Home-use nebulizers: a potential primary source of Burkholderia cepacia and other colistin-resistant, gram-negative bacteria in patients with cystic fibrosis.

G R Hutchinson1, S Parker, J A Pryor, F Duncan-Skingle, P N Hoffman, M E Hodson, M E Kaufmann, T L Pitt.   

Abstract

Inhalation of aerosols contaminated with gram-negative bacteria generated from home-use nebulizers used by cystic fibrosis (CF) patients may be a primary route for bacterial colonization of the lung. Burkholderia cepacia was isolated from 3 of [corrected] 35 home-use nebulizers, and Stenotrophomonas maltophilia was isolated from 4 of 35 home-use nebulizers. Sputum cultures for two patients whose nebulizers were contaminated with B. cepacia did not yield the organism. However, DNA macrorestriction analysis by pulsed-field gel electrophoresis confirmed that one of two strains of B. cepacia recovered from the nebulizer of a third patient was also present in the sputum of that patient. Although Pseudomonas aeruginosa was isolated from 34 patients, none of the nebulizers were positive for the organism. Sixty-nine percent of nebulizers were contaminated, and up to 16 different environmental colistin-resistant, gram-negative species were identified. The heaviest contamination was found beneath the chamber atomizer. A questionnaire survey showed that the majority of patients (28 of 34) were receiving nebulized colistin and/or gentamicin. Patients who followed recommended instructions for good nebulizer hygienic practice and paid particular attention to drying had minimal or no contamination of their nebulizers.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8904419      PMCID: PMC228851          DOI: 10.1128/jcm.34.3.584-587.1996

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  17 in total

1.  Transmission of Pseudomonas cepacia among cystic fibrosis patients.

Authors:  L Millar-Jones; A Paull; Z Saunders; M C Goodchild
Journal:  Lancet       Date:  1992-08-22       Impact factor: 79.321

2.  Transmission of gram-negative bacilli to asthmatic children via home nebulizers.

Authors:  M R Wexler; F S Rhame; M N Blumenthal; S B Cameron; B A Juni; L A Fish
Journal:  Ann Allergy       Date:  1991-03

3.  A national survey of nebuliser use.

Authors:  H J Childs; C A Dezateux
Journal:  Arch Dis Child       Date:  1991-11       Impact factor: 3.791

4.  Pseudomonas cepacia in cystic fibrosis: transmissibility and its implications.

Authors:  S Walters; E G Smith
Journal:  Lancet       Date:  1993-07-03       Impact factor: 79.321

5.  Evidence for transmission of Pseudomonas cepacia by social contact in cystic fibrosis.

Authors:  J R Govan; P H Brown; J Maddison; C J Doherty; J W Nelson; M Dodd; A P Greening; A K Webb
Journal:  Lancet       Date:  1993-07-03       Impact factor: 79.321

6.  Case-control and vector studies of nosocomial acquisition of Pseudomonas cepacia in adult patients with cystic fibrosis.

Authors:  D R Burdge; E M Nakielna; M A Noble
Journal:  Infect Control Hosp Epidemiol       Date:  1993-03       Impact factor: 3.254

7.  Epidemic of Pseudomonas cepacia in an adult cystic fibrosis unit: evidence of person-to-person transmission.

Authors:  D L Smith; L B Gumery; E G Smith; D E Stableforth; M E Kaufmann; T L Pitt
Journal:  J Clin Microbiol       Date:  1993-11       Impact factor: 5.948

8.  Clinical features of Pseudomonas cepacia pneumonia in an epidemic among immunocompromised patients.

Authors:  Y Yamagishi; J Fujita; K Takigawa; K Negayama; T Nakazawa; J Takahara
Journal:  Chest       Date:  1993-06       Impact factor: 9.410

9.  Domiciliary metaproterenol nebulization: a bacteriologic survey.

Authors:  V Popa; C G Mays; B Munkres
Journal:  J Allergy Clin Immunol       Date:  1988-08       Impact factor: 10.793

10.  Recovery of Pseudomonas cepacia and other Pseudomonas species from the environment.

Authors:  J E Mortensen; M C Fisher; J J LiPuma
Journal:  Infect Control Hosp Epidemiol       Date:  1995-01       Impact factor: 3.254

View more
  28 in total

1.  Evaluation of three oligonucleotide primer sets in PCR for the identification of Burkholderia cepacia and their differentiation from Burkholderia gladioli.

Authors:  F E Clode; M E Kaufmann; H Malnick; T L Pitt
Journal:  J Clin Pathol       Date:  1999-03       Impact factor: 3.411

2.  2007 Guideline for Isolation Precautions: Preventing Transmission of Infectious Agents in Health Care Settings.

Authors:  Jane D Siegel; Emily Rhinehart; Marguerite Jackson; Linda Chiarello
Journal:  Am J Infect Control       Date:  2007-12       Impact factor: 2.918

3.  Exceptionally high representation of Burkholderia cepacia among B. cepacia complex isolates recovered from the major Portuguese cystic fibrosis center.

Authors:  Mónica V Cunha; Ana Pinto-de-Oliveira; Luís Meirinhos-Soares; Maria José Salgado; José Melo-Cristino; Susana Correia; Celeste Barreto; Isabel Sá-Correia
Journal:  J Clin Microbiol       Date:  2007-03-14       Impact factor: 5.948

4.  Role of anti-pseudomonal antibiotics in the emergence of Stenotrophomonas maltophilia in cystic fibrosis patients.

Authors:  M Denton; N J Todd; J M Littlewood
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1996-05       Impact factor: 3.267

5.  Identification and characterization of a novel DNA marker associated with epidemic Burkholderia cepacia strains recovered from patients with cystic fibrosis.

Authors:  E Mahenthiralingam; D A Simpson; D P Speert
Journal:  J Clin Microbiol       Date:  1997-04       Impact factor: 5.948

Review 6.  Stenotrophomonas maltophilia: an emerging global opportunistic pathogen.

Authors:  Joanna S Brooke
Journal:  Clin Microbiol Rev       Date:  2012-01       Impact factor: 26.132

7.  Identification of airborne dissemination of epidemic multiresistant strains of Pseudomonas aeruginosa at a CF centre during a cross infection outbreak.

Authors:  A M Jones; J R W Govan; C J Doherty; M E Dodd; B J Isalska; T N Stanbridge; A K Webb
Journal:  Thorax       Date:  2003-06       Impact factor: 9.139

Review 8.  Infection control in cystic fibrosis.

Authors:  Lisa Saiman; Jane Siegel
Journal:  Clin Microbiol Rev       Date:  2004-01       Impact factor: 26.132

9.  Molecular epidemiology of Stenotrophomonas maltophilia isolated from clinical specimens from patients with cystic fibrosis and associated environmental samples.

Authors:  M Denton; N J Todd; K G Kerr; P M Hawkey; J M Littlewood
Journal:  J Clin Microbiol       Date:  1998-07       Impact factor: 5.948

10.  Environmental Burkholderia cepacia complex isolates in human infections.

Authors:  Adam Baldwin; Eshwar Mahenthiralingam; Pavel Drevinek; Peter Vandamme; John R Govan; David J Waine; John J LiPuma; Luigi Chiarini; Claudia Dalmastri; Deborah A Henry; David P Speert; David Honeybourne; Martin C J Maiden; Chris G Dowson
Journal:  Emerg Infect Dis       Date:  2007-03       Impact factor: 6.883

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.